CITIUS PHARMACEUTICALS INC (CTXR) Stock Overview
USA - NASDAQ:CTXR - US17322U3068 - Common Stock
CTXR Key Statistics, Chart & Performance
The current stock price of CTXR is 1.15 USD. In the past month the price decreased by -8.73%. In the past year, price decreased by -91.19%.
CTXR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.25 | 706.99B | ||
| JNJ | JOHNSON & JOHNSON | 17.66 | 425.26B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.11 | 264.56B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.88 | 237.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.11 | 235.54B | ||
| MRK | MERCK & CO. INC. | 10.38 | 199.72B | ||
| PFE | PFIZER INC | 7.12 | 137.19B | ||
| SNY | SANOFI-ADR | 10.49 | 114.34B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.67 | 91.41B | ||
| GSK | GSK PLC-SPON ADR | 8.96 | 81.63B | ||
| ZTS | ZOETIS INC | 22.93 | 63.20B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.93 | 47.56B |
Related stock screener links
About CTXR
Company Profile
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is headquartered in Cranford, New Jersey and currently employs 23 full-time employees. The company went IPO on 2017-08-03. The firm's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The firm is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
Company Info
CITIUS PHARMACEUTICALS INC
11 Commerce Dr Fl 1
Cranford NEW JERSEY 07016 US
CEO: Myron Holubiak
Employees: 23
Phone: 19089676677
CITIUS PHARMACEUTICALS INC / CTXR FAQ
What is the stock price of CITIUS PHARMACEUTICALS INC today?
The current stock price of CTXR is 1.15 USD. The price decreased by -0.86% in the last trading session.
What is the ticker symbol for CITIUS PHARMACEUTICALS INC stock?
The exchange symbol of CITIUS PHARMACEUTICALS INC is CTXR and it is listed on the Nasdaq exchange.
On which exchange is CTXR stock listed?
CTXR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CITIUS PHARMACEUTICALS INC stock?
9 analysts have analysed CTXR and the average price target is 5.1 USD. This implies a price increase of 343.48% is expected in the next year compared to the current price of 1.15. Check the CITIUS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CITIUS PHARMACEUTICALS INC worth?
CITIUS PHARMACEUTICALS INC (CTXR) has a market capitalization of 19.56M USD. This makes CTXR a Nano Cap stock.
How many employees does CITIUS PHARMACEUTICALS INC have?
CITIUS PHARMACEUTICALS INC (CTXR) currently has 23 employees.
What are the support and resistance levels for CITIUS PHARMACEUTICALS INC (CTXR) stock?
CITIUS PHARMACEUTICALS INC (CTXR) has a support level at 1.14 and a resistance level at 1.15. Check the full technical report for a detailed analysis of CTXR support and resistance levels.
Should I buy CITIUS PHARMACEUTICALS INC (CTXR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTXR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTXR, evaluating the profitability, health, valuation and growth aspects
- CITIUS PHARMACEUTICALS INC (CTXR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CITIUS PHARMACEUTICALS INC (CTXR) Sales and EPS estimates to see what analysts future expectations are.
- CITIUS PHARMACEUTICALS INC (CTXR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CITIUS PHARMACEUTICALS INC (CTXR) Insider and Institutional Ownership to learn about the owners and their transactions.
- CITIUS PHARMACEUTICALS INC (CTXR) Stock Chart to make your own analysis
- CITIUS PHARMACEUTICALS INC (CTXR) Latest news and press-releases to stay up to date.
Does CITIUS PHARMACEUTICALS INC (CTXR) stock pay dividends?
CTXR does not pay a dividend.
When does CITIUS PHARMACEUTICALS INC (CTXR) report earnings?
CITIUS PHARMACEUTICALS INC (CTXR) will report earnings on 2025-12-26, after the market close.
What is the Price/Earnings (PE) ratio of CITIUS PHARMACEUTICALS INC (CTXR)?
CITIUS PHARMACEUTICALS INC (CTXR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.96).
What is the Short Interest ratio of CITIUS PHARMACEUTICALS INC (CTXR) stock?
The outstanding short interest for CITIUS PHARMACEUTICALS INC (CTXR) is 4.81% of its float. Check the ownership tab for more information on the CTXR short interest.
CTXR Technical Analysis
CTXR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTXR. CTXR may be in some trouble as it scores bad on both profitability and health.
CTXR Financial Highlights
Over the last trailing twelve months CTXR reported a non-GAAP Earnings per Share(EPS) of -4.96. The EPS decreased by -71.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.1% | ||
| ROE | -63.01% | ||
| Debt/Equity | 0.02 |
CTXR Forecast & Estimates
9 analysts have analysed CTXR and the average price target is 5.1 USD. This implies a price increase of 343.48% is expected in the next year compared to the current price of 1.15.